Humana Quits Commercial

Article

Humana Quits Commercial

March 22, 2023
Authors
Topics

Welcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.

humana building

Humana recently announced that it will terminate its employer group line of business. This may make sense for Humana for two reasons: government programs currently provide a much higher ROI compared to commercial/employer business, and the company enjoys a strong Medicare Advantage (MA) market position (second only to United Healthcare Group) but has suffered from low market share in its commercial lines. By 2021, commercial lives contributed only 6% of the company’s revenue.

Humana By the Numbers

  • “Per capita” premium revenue is ~3.6x higher for its Medicare Advantage members versus its commercial/employer lives
  • Medical loss ratio is similar between its overall government business and its overall Group & Special business (~88% and ~83%, respectively); given the higher per capita premium, this means a higher gross margin for Humana
  • Operating Cost Ratio is ~60% less on the government side, again suggesting higher margins
  • Based on membership volumes and the premiums received, Humana’s government program total earnings are 13x higher than those for its commercial/employer business

Expanding commercial volume inevitably requires stealing share from other insurers, while Medicare Advantage also offers the opportunity to convert fee-for-service Medicare lives to Medicare Advantage. However, by putting most of its eggs in one basket (Medicare Advantage), Humana increases its vulnerability to potential legislative changes to the program that may reduce the financial attractions. For example, CMS’ 2024 Advance Notice might reduce Medicare Advantage spending by an average of $540 per Medicare Advantage enrollee. 

All our best...

-- HMP Market Access Insights Team

The Latest

A stethoscope on a small pile of dollar bills.
Article
Provider Economics Drive Oncologist Consolidation

Welcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.

Taylor Crutison
Digital graphic of a businessman holding a holographic compass in his palm.
Article
An Update on What You Need to Know About Pathways

Welcome to the February 2024 edition of our Monthly Insight Series, featuring key findings from our recent column in the Journal of Clinical Pathways. The column was the first in a series on oncologists' awareness and use of pathways.

Lee Blansett
Digital illustration of healthcare workers and computer, phone, and AI icons.
Article
Oncology Insights: Clinical Decision Support

Welcome to the January 2024 edition of our Monthly Insight Series. This month we are discussing clinical decision support systems in oncology.

Chris Van Denburg